Advanced search
Publication Cover
Leukemia & Lymphoma Volume 44, 2003 - Issue 1
Submit an article Journal homepage
14
Views
13
CrossRef citations to date
0
Altmetric
Research Article

Prognostic Significance of 18 F-fluorodeoxyglucose Positron Emission Tomography in Lymphoma

Martin R. Weihrauch Department of Internal Medicine I, University of Cologne, Cologne, Germany
,
Markus Dietlein Department of Nuclear Medicine, University of Cologne, Cologne, Germany
,
Harald Schicha Department of Nuclear Medicine, University of Cologne, Cologne, Germany
,
Volker Diehl Department of Internal Medicine I, University of Cologne, Cologne, Germany
&
Hans Tesch Practice for Hematology and Oncology, Frankfurt, Germany
Pages 15-22 | Published online: 01 Jul 2009

  • Sieber, M., Engert, A. and Diehl, V. (2000) "Treatment of Hodgkin's disease: results and current concepts of the German Hodgkin's Lymphoma Study Group", Ann. Oncol. 11(suppl. 1), 81-85.
  • Rube, C., Nguyen. T.P., Kloss. M., Loeffler. M., Trumper, L. and Pfreunschuh, M. (2001) "Consolidation radiotherapy to bulky disease in aggressive NHL. First results of the NHL B-94 trial of the DSHNHL", Ann. Hematol. 80(suppl. 3.), B84-B85.
  • Josting, A., Katay, I., Rueffer, U., Winter, S., Tesch, H., Engert, A., Diehl, V. and Wickramanayake, P.D. (1998) "Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM)", Ann. Oncol. 9. 289-295.
  • Shipp M.A., Neuberg, D., Janicek, M., Canellos, G.P. and Shulman. L.N. (1995) "High-dose CHOP as initial therapy for patients with Poor-prognosis aggressive non-Hodgkin's lymphoma: a dosefinding pilot study", J. Clin. Oncol. 13, 2916-2913.
  • Martelli, M., Vignetti, M., Zinzani, P.L., Gherlinzoni, F., Meloni, G., Fiacchini, M., De, S., Papa, G., Martelli, M.F., Calabresi, F., Tura. S. and Mandelli, F. (1996) "High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone. cisplatin, and cytarabine in aggressive non-Hodgkin's luymphoma with partial response to front-line chemotherap: a prospective randomized Italian multicenter study", J. Clin. Oncol. 14,534-542.
  • Vose, J.M., Anderson, J.R., Kessinger, A., Bierman, P.J., Coccia, P., Reed, E.C., Gordon, B. and Armitage, J. O. (1993) "High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma", J. Clin. Oncol. 11. 1846-1851.
  • Coiffier, B. (1999) "How to interpret the radiological abnormalities that persist after treatment in non-Hodgkin's lymphoma patients?", Ann. Oncol. 10,1141-1143.
  • Radford, J.A., Cowan, R.A., Flanagan. M., Dunn, G., Growther, D., Johnson, R.J. and Eddleston. B. (1988) "The significance of residual mediastinal abnormality on the chest rediograph following treatment for Hodgkin's disease [see comments]", J. Clin. Oncol. 6, 940-946.
  • Glenn, L.D. and Kumar, p.p. (1991) "The residual mideastinal mass following radiation therapy for Hodgkin's disease", Am, J. Clin. Oncol. 14. 16-24.
  • Coiffier, B., Gisselbrecht, C., vose, J.M., Tilly, H., Herbrecht, R., Bosly,. and Armitage, J.O. (1991) "Prognostic factors in aggressive malignant lymphomas: Description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs", J. Clin. Oncol. 9. 211-219.
  • Jochelson, M., Mauch, P., Balikian, J., Rosenthal, D. and Canellos G. (1985) "The significance of the residual mediastinal mass in treated Hodgkin's disease", J. clin. Oncol. 3, 637-640.
  • Israel, O., Front, D., Lam. M., Ben Haim, S., Kleinhaus, U., Ben Shachar, M., Robinson, E. and Kolodny, G.M. (1988) "Gallium 67 imaging in monitoring lymphoma response to treatment", Cancer 61,2439-2443.
  • Canellos, G.P. (1988) "Residual mass in lumphoma may not be residual disease", J. Clin. Oncol. 6, 931-933.
  • Sarrazin, R. and Dyon, J.F. (1992) "Mediastinascopy", Rev. Mal. Respir. 9.99-110.
  • Weber, W.A., Schwaiger, M. and Avril, N. (2000) "Quantitative assessment of tumor metabolism using FDG-PET imaging", Nael. Med. Biol. 27.683-687.
  • Kostakoglu, L., Yeh, S.D., Portlock, C., Heelan. R., Yao, T.J., Niedwiecki, D. and Larson, S.M. (1992) "Validation of gallium-67-citrate single-photon emission computed tomography in biopsy-confirmed residual Hodgkin's disease in the mediastinum", J. Nucl. Med. 33, 345-350.
  • Setoain, F.J., Pons, E., Herranz, R., Vidal-Sicart, S., Lomena, F., Ayuso, C., Montserrat, E. and Setoain, J. (1997) "67 Ga scintigraphy for the evaluation of recurrences and residual masses in patients with lymphoma", Nucl. Med. Commun. 18, 405-411.
  • Okada, J., Yoshikawa, K., Imazeki, K., Minoshima, S., Uno, K., Itami, J., Kuyama, J., Maruno. H. and Arimizu, N. (1991) "The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis". J. Nucl. Med. 32, 686-691.
  • Stumpe, K.D., Urbinelli, M., Steinert, H.C., Glarzmann, C., Buck. A. and von Schulthess, G.K. (1998) "Whole-body positron emission tomography using fluorodeoxyglucose for staging of lyumphoma: effectiveness and comparison with computed tomography", Eur. J. Nucl. Med. 25, 721-728.
  • Jerusalem, G., Warland, V., Najjar, F., Paulus, P., Fassotte, M.F., Fillet, G. and Rigo. P. (1999) "Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-hodgkin's lymphoma", Nucl. Med. Commun. 20. 13-20.
  • Bangerter, M., Moog, F., Buchmann, I., Kotzerke, J., Griesshammer, M., Hafner, M., Elsner, K., Frickhofen, N., Reske, S.N. and Bergmann, L. (1998) "Whole-body 2-[18 F]-fluoro-1-deoxy-D-glucose positron emission tomography (FDGPET) for accurate staging of Hodgkin's disease", Ann. Oncol. 9. 1117-1122.
  • Hoh, C.K., Glaspy, J., Rosen, P., Dahlbom, M., Lee, S.J., Kunkel. L., Hawkin, R.A., Maddahi, J. and Phelps, M.E. (1997) "Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma", J. Nucl. Med. 38, 343-348.
  • Jerusalem, G., Beguin, Y., Fassotte, M.F., Najjar, F., Paulus, P., Rigo. P. and Fillet, G. (2001) "Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with hudgkin's disease", Haematologica 86, 266-273.
  • Partridge, S., Timothy, A., O'Doherty, M.J., Hain, S.F., Rankin, S. and Mikhaeel. G. (2000) "2-Flurine-18-fluro-2-deoxy-d glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution [In Process Citation]", Ann. Oncol. 11, 1273-1279.
  • Weihrauch, M.R., Re, D., Bischoff, S., Dietlein, M., Scheidhauer, K., Krug, N., Textoris. F., Ansen. S. Franklin, J., Bohlen. H., Wolf, J., Schicha. H., Diehl, V. and Tesch, H. (2002) "Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease". Ann. Hematol. 81,20-25.
  • Kostakoglu, L. and Goldsmith, S.J. (2000) "Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears? [In Process Citation]", Eur. J. Nucl. Med. 27, 1564-1578.
  • de Wit, M., Bumann, D., Beyer, W., Herbst, K., Clausen, M. and Hossfeld, D.K. (1997) "Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma", Ann. Oncol. 8(Suppl. 1), 57-60.
  • Jerusalem, G., Beguin, Y., Fassotte, M.F., Najjar, F., Paulus, P., Rigo, P. and Fillet, G. (1999) "Whole-body positron emission tomography using 18F-flourodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging", Blood 94, 429-433.
  • Cremerius, U., Fabry, U., Neuerburg, J., Zimmy, M., Bares, R., Osieka, R. And Buell, U. (2001) "Prognostic significance of positron emission tomography using fluorine 18-fluorodeoxyglucose in patients treated for malignant lymphoma". Nuklearmedizin 40. 23-30.
  • Pichler, R., Maschek. W., Hatzl-Griesenhofer, M., Huber, H., Wimmer, G., Wahl, G. and Fridrik, M. (2000) "Clinical value of FDGPET using coincident gamma cameras in staging and restaging of malignant lymphoma-compared with conventional diagnostic methods", Nuklearmedizin 39, 166-173.
  • Naumann, R., Vaic, A., Beuthien-Baumann, B., Bredow, J., Kropp, J., Kittner. T., Franke, W.G. and Ehninger, G. (2001) "Prognostic value of positron emission tomography in the evaluation of postreatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma", Br. J. Haematol. 115, 793-800.
  • Becherer, A., Mitterbauer, M., Jaeger, U., Kaths, P., Greinix,. T., Karanikas, G., Potzi, C., Raderer, M., Dudezak. R. and Kletter, K. (2002) "Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high dose therapy with stem cell transplantation", Leukemia 16, 260-267.
  • de Wit, M., Bohuslavizki, K.H., Buchert, R., Bumann, D., Clausen. M. and Hossfeld, D.K. (2001) "18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's Lymphoma", Ann. Oncol. 12,29-37.
  • Dittmann, H., Sokler, M., Kollmannsberger, C., Dohmen, B.M., Baumann, C., Kopp. A., Bares, R., Claussen, C.D., Kanz, L. and Bokemeyer, C. (2001) "Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma". Oncol Rep. 8. 1393-1399.
  • Weihrauch, M.R., Re, D., Scheidhauer, K., Ansen, S., Dietlein, M., Bischoff, S., Bohlen, H., Wolf, J., Schicha, H., Diehl, V. and Tesch, H. (2001) "Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease", Blood 98, 2930-2934.
  • Spaepen, K., Stroobants, S., Dupont, P., Thomas, 3., Vandenberghe, P., Balzarini, J., Wolf-peeters, C., Mortelmans, L and Verhoef. G. (2001) "Can positron emission tomography with [(18)F]-flourodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?", Br. J. Haematol. 115, 272-278.
  • Spaepen. K., Stroobants, S., Dupont, P., Van Steenweghen, S., Thomas, J., Vandenberghe, P., Vanuytsel, L., Bormans, G., Balzarni, J.,Wolf-Peeters, C., Mortelmans, L. and Verhoef, G. (2001) "Prognostic value of positron emission temography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?", J. Clin. Oncol. 19, 414-419.
  • Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Thomas, J., de Groot. T., Balzarini, J., de Wolf-Peeters, C., Mortelmans, L. and Verhoef, G. (2002) "Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non Hodgkin's lymphoma", Ann. Oncol., In press.
  • Cremerius, U., Fabry, U., Wildberger, J.E., Zimny, M., Reinartz, P., Nowak, U., Schaefer, U., Buell, U. and Osieka. R. (2002) "Pretransplant positron emission tomography (PET) using Fluorine-18Fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma", Bone Marrow Transplant., In press.
  • Weinblatt, M.E., Zanzi, I., Belakhlef. A., Babchyck, B. and Kochen, J. (1997) "False-positive FDG-PET imaging of the thymus of a child with Hodgkin's disease", J. Nucl. Med. 38, 888-890.
  • de wit. M., Bumanr, D., Beyer, W., Herbst, K., Clausen, M. and Hossfeld, D.K. (1997) "Whole-body positron emission tomograpby (PET) for diagnosis of residual mass in patients with lymphoma", Ann. Oncol. 8(Suppl. 1), 57-60.
  • de Wit, M., Bohuslavizki, K.H., Buchert, R., Bumann. D., Clausen, M. and Hossfeld, D.K. (2001) "18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lumphoma", Ann. Oncol. 12. 29-37.
  • Jerusalem, G., Beguin, Y., Fassotte, M.F., Najjar, F., paulus, P., Rigo, P. and Fillet, G. (1999) "Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging", Blood 94, 429-433.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.